Several other equities analysts also recently commented on the stock. Canaccord Genuity reissued a hold rating and issued a $7.00 price objective on shares of OraSure Technologies in a research note on Wednesday, August 14th. Zacks Investment Research cut shares of OraSure Technologies from a hold rating to a sell rating in a research report on Tuesday, July 9th. Three research analysts have rated the stock with a sell rating and one has issued a hold rating to the company. The stock currently has an average rating of Sell and an average target price of $7.00.
Shares of OraSure Technologies stock traded down $0.01 on Thursday, reaching $7.59. 371,360 shares of the stock were exchanged, compared to its average volume of 565,494. The firm’s 50 day moving average is $7.40 and its 200-day moving average is $9.05. OraSure Technologies has a one year low of $6.35 and a one year high of $16.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.13 and a current ratio of 6.99. The firm has a market cap of $468.80 million, a PE ratio of 21.70, a P/E/G ratio of 1.64 and a beta of 1.27.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its position in OraSure Technologies by 3.0% in the 2nd quarter. BlackRock Inc. now owns 9,391,915 shares of the medical instruments supplier’s stock valued at $87,157,000 after acquiring an additional 273,670 shares during the period. Renaissance Technologies LLC increased its position in OraSure Technologies by 14.0% in the 2nd quarter. Renaissance Technologies LLC now owns 4,965,803 shares of the medical instruments supplier’s stock valued at $46,083,000 after acquiring an additional 610,300 shares during the period. D. E. Shaw & Co. Inc. increased its position in OraSure Technologies by 67.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,971,866 shares of the medical instruments supplier’s stock valued at $27,579,000 after acquiring an additional 1,193,709 shares during the period. Dimensional Fund Advisors LP increased its position in OraSure Technologies by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,918,182 shares of the medical instruments supplier’s stock valued at $34,084,000 after acquiring an additional 31,216 shares during the period. Finally, American Capital Management Inc. increased its position in OraSure Technologies by 67.2% in the 1st quarter. American Capital Management Inc. now owns 2,876,592 shares of the medical instruments supplier’s stock valued at $32,074,000 after acquiring an additional 1,156,560 shares during the period. Hedge funds and other institutional investors own 94.32% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Read More: Cost of Capital Explained
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.